Smadar Nestor
Corporate Officer/Principal chez MEDIWOUND LTD.
Profil
Smadar Nestor is currently the Vice President-Regulatory Affairs at MediWound Ltd.
She has previously worked as the Director-Quality Assurance & Control at ProChon Biotech Ltd., Product Manager-Regulatory Affairs at Teva Pharmaceutical Industries Ltd., and Manager-Regulatory Affairs at Collgard Biopharmaceuticals Ltd.
She has a graduate degree from Tel-Aviv University and an undergraduate degree from The Hebrew University of Jerusalem.
Postes actifs de Smadar Nestor
Sociétés | Poste | Début |
---|---|---|
MEDIWOUND LTD. | Corporate Officer/Principal | 01/01/2008 |
Anciens postes connus de Smadar Nestor
Sociétés | Poste | Fin |
---|---|---|
TEVA PHARMACEUTICAL INDUSTRIES LIMITED | General Counsel | - |
ProChon Biotech Ltd.
ProChon Biotech Ltd. Pharmaceuticals: MajorHealth Technology ProChon Biotech, Ltd. manufactures innovative growth factor-based therapies in regenerative medicine and orthopedics. The company was founded by Avner Yayon in 1995 and is headquartered in Tel Aviv, Israel. | Corporate Officer/Principal | - |
Collgard Biopharmaceuticals Ltd.
Collgard Biopharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Collgard Biopharmaceuticals, the tissue therapeutics company, is developing drug treatments that target disease progression by directly influencing the tissue regeneration process. Central to Collgard's novel approach is its lead drug candidate, Tempostatin (Halofuginone hydrobromide). Tempostatin is a multi-indication, small-molecule drug candidate that has been identified by the company as influencing a 'master switch' in the body's tissue repair process. As a potent and selective regulator of stromal cell activation, cell migration and excessive collagen type I synthesis, Tempostatin makes it possible to harness and direct the tissue repair process for treating diseases acting at the tissue level. Collgard is developing therapeutic solutions for several clinical indications with significant unmet clinical needs. These solutions are based on highly specific control of the tissue repair process. Current programs target the following indications vascular restenosis, end-organ fibrosis, selected cancers and dermal fibroproliferative disorders. Tempostatin holds exceptional promise based on addressing a fundamental underlying pathological process that is not accessible to other current therapeutic approaches. In developing Tempostatin, Collgard seeks to offer novel therapeutic solutions as well as extend the effectiveness of existing therapies. Founded in 1996, Collgard Biopharmaceuticals is a privately held, clinical stage company, led by a global team of medical and drug development experts based in Atlanta and Tel Aviv. Scientific and clinical collaborators include The Mayo Clinic, the U.S. NCI, the EORTC, and Harvard Medical School. Collgard was founded by Medica Venture Partners. Additional investors include Mayo Medical Ventures, Denali Ventures, Yozma Group, and Comsor. | General Counsel | - |
Formation de Smadar Nestor
Tel-Aviv University | Graduate Degree |
The Hebrew University of Jerusalem | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 2 |
---|---|
TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Health Technology |
MEDIWOUND LTD. | Health Technology |
Entreprise privées | 2 |
---|---|
Collgard Biopharmaceuticals Ltd.
Collgard Biopharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Collgard Biopharmaceuticals, the tissue therapeutics company, is developing drug treatments that target disease progression by directly influencing the tissue regeneration process. Central to Collgard's novel approach is its lead drug candidate, Tempostatin (Halofuginone hydrobromide). Tempostatin is a multi-indication, small-molecule drug candidate that has been identified by the company as influencing a 'master switch' in the body's tissue repair process. As a potent and selective regulator of stromal cell activation, cell migration and excessive collagen type I synthesis, Tempostatin makes it possible to harness and direct the tissue repair process for treating diseases acting at the tissue level. Collgard is developing therapeutic solutions for several clinical indications with significant unmet clinical needs. These solutions are based on highly specific control of the tissue repair process. Current programs target the following indications vascular restenosis, end-organ fibrosis, selected cancers and dermal fibroproliferative disorders. Tempostatin holds exceptional promise based on addressing a fundamental underlying pathological process that is not accessible to other current therapeutic approaches. In developing Tempostatin, Collgard seeks to offer novel therapeutic solutions as well as extend the effectiveness of existing therapies. Founded in 1996, Collgard Biopharmaceuticals is a privately held, clinical stage company, led by a global team of medical and drug development experts based in Atlanta and Tel Aviv. Scientific and clinical collaborators include The Mayo Clinic, the U.S. NCI, the EORTC, and Harvard Medical School. Collgard was founded by Medica Venture Partners. Additional investors include Mayo Medical Ventures, Denali Ventures, Yozma Group, and Comsor. | Health Technology |
ProChon Biotech Ltd.
ProChon Biotech Ltd. Pharmaceuticals: MajorHealth Technology ProChon Biotech, Ltd. manufactures innovative growth factor-based therapies in regenerative medicine and orthopedics. The company was founded by Avner Yayon in 1995 and is headquartered in Tel Aviv, Israel. | Health Technology |